First AD

Second AD

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Oncology Nursing News

The OncLive Nursing News condition center page is a comprehensive resource for clinical news and expert insights for oncology nurses and their best practices for treating patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research across malignancies that can be beneficial for oncology nurses.

Supportive Care

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia

Peer Exchange

Venetoclax in R/R CLL

Risk Assessment in Newly Diagnosed CLL

Up-front Ibrutinib Versus FCR for Patients With CLL

Frontline Antibodies With BTK Inhibitors for CLL

Toxicities With BTK Inhibitors for CLL

Comparison of BTK Inhibitors for CLL

Obinutuzumab + Venetoclax for Frontline CLL

MRD Testing for CLL

Ibrutinib + Venetoclax for Frontline CLL

Resistance Mechanisms Associated With BTK Inhibitors

Progression on Frontline Ibrutinib in CLL

BTK Inhibitors in R/R CLL

PI3K Inhibitors in R/R CLL

Novel Combinations in Development for CLL

Final Thoughts From ASH 2019 in CLL